Shares of Pain Therapeutics (NASDAQ:PTIE) were down 3.1% during trading on Tuesday . The company traded as low as $2.18 and last traded at $2.18, with a volume of 132,386 shares traded. The stock had previously closed at $2.25.

Separately, Zacks Investment Research downgraded shares of Pain Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th.

The firm’s market cap is $98.74 million. The company has a 50 day moving average price of $2.18 and a 200-day moving average price of $2.06.

Pain Therapeutics (NASDAQ:PTIE) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.03. Analysts predict that Pain Therapeutics will post ($0.57) earnings per share for the current fiscal year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.